COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021

Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and Pfizer-BioNTech) in Korea. This report provides a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyun-kyung Oh, Eun Kyeong Kim, Insob Hwang, Tae Eun Kim, Yeon-kyeong Lee, Eunju Lee, Yeon-Kyeng Lee
Formato:	article
Lenguaje:	EN
Publicado:	Korea Centers for Disease Control & Prevention 2021
Materias:	adverse event covid-19 safety vaccines Special situations and conditions RC952-1245 Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/746eac96b8f44b9086be3b35990bd9aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:746eac96b8f44b9086be3b35990bd9aa
record_format	dspace
spelling	oai:doaj.org-article:746eac96b8f44b9086be3b35990bd9aa2021-11-05T00:06:00ZCOVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 20212210-90992210-911010.24171/j.phrp.2021.0157https://doaj.org/article/746eac96b8f44b9086be3b35990bd9aa2021-08-01T00:00:00Zhttp://ophrp.org/upload/pdf/j-phrp-2021-0157.pdfhttps://doaj.org/toc/2210-9099https://doaj.org/toc/2210-9110Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and Pfizer-BioNTech) in Korea. This report provides a summary of adverse events following COVID-19 vaccination as of April 30, 2021. Methods Adverse events following immunization are notifiable by medical doctors to the Korea Immunization Management System (KIMS) under the national surveillance system. We analyzed all adverse events reports following COVID-19 vaccination to the KIMS from February 26 to April 30, 2021. Results In total, 16,196 adverse events following 3,586,814 administered doses of COVID-19 vaccines were reported in approximately 2 months (February 26 to April 30, 2021). Of these, 15,658 (96.7%) were non-serious adverse events, and 538 (3.3%) were serious adverse events, including 73 (0.5%) deaths. The majority of adverse events (n=13,063, 80.7%) were observed in women, and the most frequently reported adverse events were myalgia (52.2%), fever (44.9%), and headache (34.9%). Of the 73 deaths following the COVID-19 vaccination, none were related to the vaccines. Conclusion By April 30, 3.6 million doses of the COVID 19 vaccine had been given in Korea, and the overwhelming majority of reports were for non-serious events. The Korea Disease Control and Prevention Agency continues to monitor the safety of COVID-19 vaccination.Hyun-kyung OhEun Kyeong KimInsob HwangTae Eun KimYeon-kyeong LeeEunju LeeYeon-Kyeng LeeKorea Centers for Disease Control & Preventionarticleadverse eventcovid-19safetyvaccinesSpecial situations and conditionsRC952-1245Infectious and parasitic diseasesRC109-216ENOsong Public Health and Research Perspectives, Vol 12, Iss 4, Pp 264-268 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adverse event covid-19 safety vaccines Special situations and conditions RC952-1245 Infectious and parasitic diseases RC109-216
spellingShingle	adverse event covid-19 safety vaccines Special situations and conditions RC952-1245 Infectious and parasitic diseases RC109-216 Hyun-kyung Oh Eun Kyeong Kim Insob Hwang Tae Eun Kim Yeon-kyeong Lee Eunju Lee Yeon-Kyeng Lee COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
description	Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and Pfizer-BioNTech) in Korea. This report provides a summary of adverse events following COVID-19 vaccination as of April 30, 2021. Methods Adverse events following immunization are notifiable by medical doctors to the Korea Immunization Management System (KIMS) under the national surveillance system. We analyzed all adverse events reports following COVID-19 vaccination to the KIMS from February 26 to April 30, 2021. Results In total, 16,196 adverse events following 3,586,814 administered doses of COVID-19 vaccines were reported in approximately 2 months (February 26 to April 30, 2021). Of these, 15,658 (96.7%) were non-serious adverse events, and 538 (3.3%) were serious adverse events, including 73 (0.5%) deaths. The majority of adverse events (n=13,063, 80.7%) were observed in women, and the most frequently reported adverse events were myalgia (52.2%), fever (44.9%), and headache (34.9%). Of the 73 deaths following the COVID-19 vaccination, none were related to the vaccines. Conclusion By April 30, 3.6 million doses of the COVID 19 vaccine had been given in Korea, and the overwhelming majority of reports were for non-serious events. The Korea Disease Control and Prevention Agency continues to monitor the safety of COVID-19 vaccination.
format	article
author	Hyun-kyung Oh Eun Kyeong Kim Insob Hwang Tae Eun Kim Yeon-kyeong Lee Eunju Lee Yeon-Kyeng Lee
author_facet	Hyun-kyung Oh Eun Kyeong Kim Insob Hwang Tae Eun Kim Yeon-kyeong Lee Eunju Lee Yeon-Kyeng Lee
author_sort	Hyun-kyung Oh
title	COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
title_short	COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
title_full	COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
title_fullStr	COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
title_full_unstemmed	COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
title_sort	covid-19 vaccine safety monitoring in the republic of korea: february 26, 2021 to april 30, 2021
publisher	Korea Centers for Disease Control & Prevention
publishDate	2021
url	https://doaj.org/article/746eac96b8f44b9086be3b35990bd9aa
work_keys_str_mv	AT hyunkyungoh covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT eunkyeongkim covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT insobhwang covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT taeeunkim covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT yeonkyeonglee covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT eunjulee covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021 AT yeonkyenglee covid19vaccinesafetymonitoringintherepublicofkoreafebruary262021toapril302021
_version_	1718444533986885632

COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021

Ejemplares similares